CN119100981A - 一种选择性钾通道调节剂的固态结晶形式 - Google Patents

一种选择性钾通道调节剂的固态结晶形式 Download PDF

Info

Publication number
CN119100981A
CN119100981A CN202411269568.3A CN202411269568A CN119100981A CN 119100981 A CN119100981 A CN 119100981A CN 202411269568 A CN202411269568 A CN 202411269568A CN 119100981 A CN119100981 A CN 119100981A
Authority
CN
China
Prior art keywords
compound
degrees
solid
state form
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411269568.3A
Other languages
English (en)
Chinese (zh)
Inventor
P·R·比克勒
J-J·A·卡迪厄
M·D·坦迪
G·N·比奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenon Pharmaceuticals Inc
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CN119100981A publication Critical patent/CN119100981A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
  • Transmitters (AREA)
  • Laminated Bodies (AREA)
  • Medicinal Preparation (AREA)
CN202411269568.3A 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式 Pending CN119100981A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962913574P 2019-10-10 2019-10-10
US62/913,574 2019-10-10
CN202080085704.7A CN115190874A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式
PCT/US2020/055129 WO2021072307A1 (en) 2019-10-10 2020-10-09 Solid state crystalline forms of a selective potassium channel modulator

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080085704.7A Division CN115190874A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式

Publications (1)

Publication Number Publication Date
CN119100981A true CN119100981A (zh) 2024-12-10

Family

ID=73040296

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202411269568.3A Pending CN119100981A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式
CN202510163354.6A Pending CN120247795A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式
CN202510163123.5A Pending CN120157617A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式
CN202080085704.7A Pending CN115190874A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510163354.6A Pending CN120247795A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式
CN202510163123.5A Pending CN120157617A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式
CN202080085704.7A Pending CN115190874A (zh) 2019-10-10 2020-10-09 一种选择性钾通道调节剂的固态结晶形式

Country Status (30)

Country Link
US (4) US11091441B2 (https=)
EP (2) EP4523687A3 (https=)
JP (1) JP2022552187A (https=)
KR (1) KR20220080119A (https=)
CN (4) CN119100981A (https=)
AU (1) AU2020364142A1 (https=)
BR (1) BR112022006583A2 (https=)
CA (1) CA3153752A1 (https=)
CL (1) CL2022000881A1 (https=)
CO (1) CO2022005890A2 (https=)
CR (1) CR20220187A (https=)
DK (1) DK4041713T3 (https=)
ES (1) ES3014703T3 (https=)
FI (1) FI4041713T3 (https=)
GE (2) GEP20247689B (https=)
HR (1) HRP20250134T1 (https=)
HU (1) HUE070295T2 (https=)
IL (2) IL292005B2 (https=)
LT (1) LT4041713T (https=)
MA (2) MA56288A1 (https=)
MX (3) MX2022004209A (https=)
PE (1) PE20221023A1 (https=)
PH (1) PH12022550854A1 (https=)
PL (1) PL4041713T3 (https=)
PT (1) PT4041713T (https=)
RS (1) RS66531B1 (https=)
SI (1) SI4041713T1 (https=)
SM (1) SMT202500101T1 (https=)
TW (1) TWI886158B (https=)
WO (1) WO2021072307A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI886158B (zh) * 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
MX2022005490A (es) 2019-11-08 2022-08-10 Xenon Pharmaceuticals Inc Metodos para el tratamiento de trastornos depresivos.
US11957675B2 (en) 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia
CA3151863C (en) 2021-10-27 2024-01-02 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator and preparation and use thereof
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用
CN120441482A (zh) * 2024-02-08 2025-08-08 上海挚盟医药科技有限公司 四氢异喹啉基化合物的晶型及其应用
WO2025179128A1 (en) 2024-02-22 2025-08-28 Xenon Pharmaceuticals Inc. Azetukalner for use in the treatment of depression, anhedonia or a seizure disorder such as epilepsy in pediatric subjects

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639385A (en) 1968-07-26 1972-02-01 Eastman Kodak Co Heterocyclic monoazo compounds from n n-diaralkyl anilines and polyester textile materials dyed therewith
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4181803A (en) 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
ATE25078T1 (de) 1982-10-27 1987-02-15 Degussa 2-amino-3-acylamino-6-benzylamino-pyridinderivate mit anti-epileptischer wirkung.
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
EP0193056B1 (de) 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Kombination von Flupirtin und anticholinergisch wirkenden Spasmolytika
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2583067B2 (ja) 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (https=) 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
US5428039A (en) 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
JP4097285B2 (ja) 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5679706A (en) 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
WO1996019233A2 (en) 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
DE19539861A1 (de) 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU8561298A (en) 1997-08-08 1999-03-01 Chugai Seiyaku Kabushiki Kaisha Remedies for complications of diabetes
US6265417B1 (en) 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6211171B1 (en) 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
BR9916162A (pt) 1998-12-14 2001-09-04 Cellegy Pharma Inc Composição e método para o tratamento de um distúrbio anorretal e para controlar a dor associada com o mesmo
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
US6451857B1 (en) 1999-03-10 2002-09-17 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
AU766648B2 (en) 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
PT1200073E (pt) 1999-07-06 2007-03-30 Lilly Co Eli Antagonistas selectivos do receptor de iglur5 para o tratamento de enxaqueca
US6472165B1 (en) 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
ATE380176T1 (de) 1999-08-04 2007-12-15 Icagen Inc Benzanilide als öffner des kaliumkanals
EP1200086A4 (en) 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
US6348486B1 (en) 2000-10-17 2002-02-19 American Home Products Corporation Methods for modulating bladder function
US6589986B2 (en) 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
US20020183395A1 (en) 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
GB0119711D0 (en) 2001-08-13 2001-10-03 Unilever Plc Process for the production of detergent granules
GB0121214D0 (en) 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (en) 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
WO2003097586A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7045551B2 (en) 2002-11-22 2006-05-16 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
ATE488231T1 (de) 2002-12-23 2010-12-15 Icagen Inc Quinazolinone als kaliumkanalmodulatoren
ES2282701T3 (es) 2002-12-27 2007-10-16 H. Lundbeck A/S Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central.
EP1606247A1 (en) 2003-03-14 2005-12-21 H. Lundbeck A/S Substituted aniline derivatives
WO2004082677A1 (en) 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
MXPA05010174A (es) 2003-04-25 2005-11-08 Lundbeck & Co As H Derivados de indol e indolina sustituidos.
WO2004105795A1 (en) 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
US7553858B2 (en) 2003-12-17 2009-06-30 Meda Pharma Gmbh & Co. Kg Combination of flupirtine and tramadol
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
AU2005233642A1 (en) 2004-04-13 2005-10-27 Astellas Pharma Inc. Polycyclic pyridines as potassium ion channel modulators
RU2006139930A (ru) 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
CA2589001A1 (en) 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for neuropathic pain
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
EP1861394A1 (en) 2005-03-03 2007-12-05 H.Lundbeck A/S Substituted pyridine derivatives
US7683058B2 (en) 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
WO2007128462A1 (en) 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
SG174095A1 (en) * 2006-08-23 2011-09-29 Valeant Pharmaceuticals Int Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
CN101578259A (zh) 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
US20090018154A1 (en) 2007-05-17 2009-01-15 Endo Pharmaceuticals, Inc., A Corporation Of Delaware Opioid and methods of making and using the same
AR070513A1 (es) 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
JP2011506391A (ja) 2007-12-11 2011-03-03 ノイロサーチ アクティーゼルスカブ カリウムチャネル活性化因子として有用な、新規の２−エチル−メチル−アミノ−３−アミド−６−アミノ−ピリジン誘導体
JP2011507800A (ja) 2007-12-26 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
US20100323016A1 (en) 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
JP2013517315A (ja) 2010-01-20 2013-05-16 グラクソ グループ リミテッド 新規組成物
CA2808501A1 (en) 2010-08-23 2012-03-01 Vertex Pharmaceuticals Incorporated Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
JP5248585B2 (ja) * 2010-12-15 2013-07-31 ゼノン・ファーマシューティカルズ・インコーポレイテッド 治療薬としてのニコチンアミド誘導体およびそれらの使用
WO2013067591A1 (en) 2011-11-10 2013-05-16 Relevare Australia Pty Ltd Topical formulations for pain management
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
SI2819998T1 (sl) 2012-03-01 2022-07-29 Array Biopharma Inc. Kristalinske oblike 1-(3-tert-butil-1-P-tolil-1H-pirazol-5-il)-3- (5-fluoro-2-(1-(2-hidroksietil)-1H-indazol-5-iloksi)benzil)urea hidroklorida
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
EP2970188A4 (en) 2013-03-15 2016-10-19 Vm Therapeutics Llc NOVEL CRYSTALLINE FORMS
DK3233786T3 (da) 2014-12-16 2022-05-09 Ptc Therapeutics Inc Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid
BR112020006796A2 (pt) 2017-10-10 2020-12-29 Khawla Abu-Izza Composições de sal de sulfassalazina e métodos de uso das mesmas
EP4241843B1 (en) 2018-02-20 2025-05-21 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
WO2019217924A1 (en) 2018-05-11 2019-11-14 Xenon Pharmaceuticals Inc. Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
TWI886158B (zh) * 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CA3151863C (en) 2021-10-27 2024-01-02 Shanghai Zhimeng Biopharma, Inc. Compound as potassium channel regulator and preparation and use thereof

Also Published As

Publication number Publication date
BR112022006583A2 (pt) 2022-06-28
PE20221023A1 (es) 2022-06-16
PL4041713T3 (pl) 2025-04-14
MA65149A1 (fr) 2026-03-31
MX2025010194A (es) 2025-10-01
CA3153752A1 (en) 2021-04-15
EP4523687A3 (en) 2025-05-21
SI4041713T1 (sl) 2025-07-31
HUE070295T2 (hu) 2025-05-28
ES3014703T3 (en) 2025-04-24
CN120157617A (zh) 2025-06-17
RS66531B1 (sr) 2025-03-31
IL292005A (en) 2022-06-01
US20220064120A1 (en) 2022-03-03
US20240279182A1 (en) 2024-08-22
SMT202500101T1 (it) 2025-05-12
IL292005B2 (en) 2025-05-01
IL292005B1 (en) 2025-01-01
CN120247795A (zh) 2025-07-04
EP4041713B1 (en) 2024-12-11
US11091441B2 (en) 2021-08-17
MX2022004209A (es) 2022-05-03
US20210147363A1 (en) 2021-05-20
KR20220080119A (ko) 2022-06-14
WO2021072307A1 (en) 2021-04-15
CO2022005890A2 (es) 2022-05-31
EP4041713B8 (en) 2025-01-15
AU2020364142A1 (en) 2022-04-21
CR20220187A (es) 2022-07-21
EP4523687A2 (en) 2025-03-19
MX2025010193A (es) 2025-10-01
EP4041713A1 (en) 2022-08-17
PH12022550854A1 (en) 2023-05-03
CL2022000881A1 (es) 2023-01-13
TW202128627A (zh) 2021-08-01
LT4041713T (lt) 2025-02-25
FI4041713T3 (fi) 2025-03-18
MA56288A1 (fr) 2023-01-31
PT4041713T (pt) 2025-02-25
TWI886158B (zh) 2025-06-11
DK4041713T3 (da) 2025-03-03
GEAP202415926A (en) 2024-07-10
IL316068A (en) 2024-12-01
CN115190874A (zh) 2022-10-14
JP2022552187A (ja) 2022-12-15
US12319657B1 (en) 2025-06-03
GEP20247689B (en) 2024-11-11
HRP20250134T1 (hr) 2025-03-28

Similar Documents

Publication Publication Date Title
CN119100981A (zh) 一种选择性钾通道调节剂的固态结晶形式
AU2014239254B2 (en) Crystalline forms of tyrosine kinase inhibitors and their salts
CN111548343B (zh) 一种高活性csf1r抑制剂化合物的制备方法
CA2962206A1 (en) Crystalline forms of tyrosine kinase inhibitors and their salts
US20180177781A1 (en) Novel crystalline forms
CN117797146A (zh) Sarm1酶活性抑制剂及其在神经退行性疾病中的应用
HK40082475A (en) Solid state crystalline forms of a selective potassium channel modulator
HK40120019A (zh) 一种选择性钾通道调节剂的固态结晶形式
HK40120546A (en) Solid state crystalline forms of a selective potassium channel modulator
EA053143B1 (ru) Твердые кристаллические формы селиктивного модулятора калиевых каналов
HK40078032B (en) Solid state crystalline forms of a selective potassium channel modulator
HK40078032A (en) Solid state crystalline forms of a selective potassium channel modulator
US20250333381A1 (en) Solid state forms
EP4431515A1 (en) Novel crystal forms of peptide boric acid compound and preparation methods therefor
CA3137209C (en) Crystalline form of compound, method for preparing the same, pharmaceutical composition and use
CN111825690B (zh) 一种phd抑制剂的新晶型及其制备方法
TW202611024A (zh) 選擇性鉀通道調節劑之固態晶型
BR122025010012A2 (pt) Formas cristalinas, forma de estado sólido e forma sólida amorfa de um modulador de canal de potássio seletivo, composições farmacêuticas, usos e métodos de preparação
TW202539674A (zh) 用作cdk4蛋白激酶抑制劑的化合物及其應用
WO2023230968A1 (zh) Shp2抑制剂、其晶型及其制备方法与用途
WO2024056079A1 (zh) 内匹司他酸加成盐的多晶型及其制备方法和用途
WO2024067085A1 (zh) 一种细胞周期蛋白依赖性激酶(cdk4/6)抑制剂的枸橼酸盐、其晶型、制备方法和用途
HK40116439A (zh) 用於egfr蛋白降解的化合物及其用途
CN119997950A (zh) 用于治疗疾病的单羧酸转运蛋白4的杂环抑制剂的盐
WO2020042972A1 (zh) 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40120019

Country of ref document: HK